查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608934

肝癌診斷市場：按測試類型和最終用戶分類 - 全球預測 2025-2030

Liver Cancer Diagnostics Market by Test Type (Biopsy, Endoscopy, Imaging), End User (Academic & Research Institutes, Hospitals & Diagnostic Laboratories, Pharmaceutical & CRO Laboratories) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肝癌診斷市場價值為94.1億美元，預計到2024年將達到100.5億美元，複合年成長率為6.62%，到2030年將達到147.4億美元。

肝癌診斷市場的定義是專注於開拓和實施早期準確檢測肝癌的技術和方法。這個市場是必要的，因為全世界肝癌的發生率正在增加，部分原因是肝炎患者的增加和生活方式相關的危險因子。肝癌診斷藥物具有廣泛的治療用途，包括篩檢、早期檢測和個人化治療計劃，並用於醫院、診斷實驗室、專科診所和其他機構。最終用途範圍從直接臨床使用到研究目的。市場成長很大程度上受到顯像模式、分子生物標記和液態切片活體組織切片等診斷工具技術進步的影響。此外，新興經濟體正在增加對醫療基礎設施的投資，提供進一步的成長潛力。潛在的商機在於開發更多非侵入性且更具成本效益的診斷測試，以提高早期檢測的準確性。公司可以利用與研究機構的夥伴關係來創新並擴大診斷工具的範圍。儘管有這些獎勵，但成長仍受到診斷程序成本高、低收入地區意識淡薄以及法規環境複雜等因素的挑戰。此外，診斷程序中的誤報和漏報可能會阻礙市場信心和採用。專注於人工智慧和機器學習以提高診斷準確性和預測分析可以推動創新。整合患者資料以製定個人化醫療保健策略的客製化診斷解決方案提供了一條有利的途徑。競爭激烈且不斷變化的市場要求企業保持敏捷、投資研發並快速回應監管變化。對於希望在這個動態環境中取得成功的市場參與企業來說，鼓勵官民合作關係並進行宣傳宣傳活動以提高意識並提高篩檢率也是重要的建議。

主要市場統計
基準年[2023] 94.1億美元
預計年份 [2024] 100.5億美元
預測年份 [2030] 147.4億美元
複合年成長率（%） 6.62%

市場動態：揭示快速發展的肝癌診斷市場的關鍵市場洞察

由於供需的動態互動，肝癌診斷藥物市場正在經歷轉型。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球肝癌發生率不斷上升
    • 肝癌診斷優勢報銷制度
    • 增加肝癌篩檢項目
  • 市場限制因素
    • 缺乏熟練且訓練有素的專業人員
  • 市場機會
    • 癌症診斷設備的技術進步
    • 專注於開發有效的診斷方法
  • 市場挑戰
    • 肝癌診斷藥物的局限性

波特五力：駕馭肝癌診斷市場的策略工具

波特的五力框架是了解肝癌診斷市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肝癌診斷藥物市場的外部影響

外部宏觀環境因素在塑造肝癌診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解肝癌診斷藥物市場競爭狀況

對肝癌診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣肝癌診斷市場供應商績效評估

FPNV定位矩陣是評估肝癌診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪肝癌診斷市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，肝癌診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球肝癌發生率增加
      • 肝癌診斷優勢保險報銷制度
      • 增加肝癌篩檢項目
    • 抑制因素
      • 熟練且訓練有素的專業人員數量有限
    • 機會
      • 癌症診斷設備的技術進步
      • 專注於開發有效的診斷方法
    • 任務
      • 肝癌診斷藥物的局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按測試類型分類的肝癌診斷藥物市場

  • 切片檢查
  • 內視鏡檢查
  • 影像
  • 臨床檢查
    • 生物標記
      • 酵素和同功異構酵素
      • 生長因子和受體
      • 分子標記
      • 癌胎抗原和糖蛋白抗原
      • 病理性生物標記
    • 驗血

第7章肝癌診斷市場：依最終用戶分類

  • 學術研究所
  • 醫院和診斷實驗室
  • 醫藥及CRO研究院

第8章北美和南美肝癌診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區肝癌診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲肝癌診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Accuray Incorporated
  • Biocartis NV
  • CR Bard Inc.
  • Elekta AB
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Medical Systems USA, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-3A2E844FE71E

The Liver Cancer Diagnostics Market was valued at USD 9.41 billion in 2023, expected to reach USD 10.05 billion in 2024, and is projected to grow at a CAGR of 6.62%, to USD 14.74 billion by 2030.

The liver cancer diagnostics market is defined by its focus on the development and implementation of technologies and methodologies to accurately detect liver cancer at its earliest stages. This market's necessity is driven by the increasing global incidence of liver cancer, partly due to rising cases of hepatitis and lifestyle-related risk factors. Applications of liver cancer diagnostics are wide-ranging, including screening, early detection, and personalized treatment plans, which are used by hospitals, diagnostic laboratories, and specialty clinics. The end-use scope extends from direct clinical applications to research purposes. Market growth is significantly influenced by technological advancements in diagnostic tools such as imaging modalities, molecular biomarkers, and liquid biopsy tests. Additionally, there are enhanced healthcare infrastructure investments in emerging economies, providing further growth potential. Potential opportunities lie in developing more non-invasive, cost-effective diagnostic tests that enhance early detection accuracy. Companies can capitalize on partnerships with research institutions to innovate and broaden the diagnostic tools landscape. Despite these incentives, growth is challenged by factors such as high costs of diagnostic procedures, limited awareness in low-income regions, and the regulatory environment's complexity. Furthermore, false positives or negatives in diagnostic procedures can hinder market trust and adoption. Innovation can thrive in focusing on artificial intelligence and machine learning to improve diagnostic accuracy and predictive analytics. Customized diagnostic solutions that integrate patient data for personalized healthcare strategies represent lucrative avenues. The nature of the market is competitive and continually evolving, requiring businesses to stay agile, invest in R&D, and adapt to regulatory changes swiftly. Encouraging public-private partnerships and fostering educational campaigns to heighten awareness and screening uptake are also crucial recommendations for market participants aiming to navigate and succeed within this dynamic landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 9.41 billion
Estimated Year [2024] USD 10.05 billion
Forecast Year [2030] USD 14.74 billion
CAGR (%) 6.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Incidence of liver cancer globally
    • Favorable reimbursement framework for liver cancer diagnosis
    • Growing number of liver cancer screening programs
  • Market Restraints
    • Limited skilled and trained professionals
  • Market Opportunities
    • Technological advancements in cancer diagnosis equipment
    • Focus on development of effective diagnostics
  • Market Challenges
    • Limitations of liver cancer diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Liver Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Cancer Diagnostics Market

A detailed market share analysis in the Liver Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Cancer Diagnostics Market

A strategic analysis of the Liver Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accuray Incorporated, Biocartis NV, C.R. Bard Inc., Elekta AB, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Medical Systems U.S.A., Inc., Illumina, Inc., Koninklijke Philips N.V., Myriad Genetics, Inc., Qiagen N.V., Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Biopsy, Endoscopy, Imaging, and Laboratory tests. The Laboratory tests is further studied across Biomarkers and Blood Tests. The Biomarkers is further studied across Enzymes & Isoenzymes, Growth Factors & Receptors, Molecular Markers, Oncofetal & Glycoprotein Antigens, and Pathological Biomarkers.
  • Based on End User, market is studied across Academic & Research Institutes, Hospitals & Diagnostic Laboratories, and Pharmaceutical & CRO Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence of liver cancer globally
      • 5.1.1.2. Favorable reimbursement framework for liver cancer diagnosis
      • 5.1.1.3. Growing number of liver cancer screening programs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited skilled and trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in cancer diagnosis equipment
      • 5.1.3.2. Focus on development of effective diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of liver cancer diagnostics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Biopsy
  • 6.3. Endoscopy
  • 6.4. Imaging
  • 6.5. Laboratory tests
    • 6.5.1. Biomarkers
      • 6.5.1.1. Enzymes & Isoenzymes
      • 6.5.1.2. Growth Factors & Receptors
      • 6.5.1.3. Molecular Markers
      • 6.5.1.4. Oncofetal & Glycoprotein Antigens
      • 6.5.1.5. Pathological Biomarkers
    • 6.5.2. Blood Tests

7. Liver Cancer Diagnostics Market, by End User

  • 7.1. Introduction
  • 7.2. Academic & Research Institutes
  • 7.3. Hospitals & Diagnostic Laboratories
  • 7.4. Pharmaceutical & CRO Laboratories

8. Americas Liver Cancer Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accuray Incorporated
  • 3. Biocartis NV
  • 4. C.R. Bard Inc.
  • 5. Elekta AB
  • 6. Epigenomics AG
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Fujifilm Medical Systems U.S.A., Inc.
  • 9. Illumina, Inc.
  • 10. Koninklijke Philips N.V.
  • 11. Myriad Genetics, Inc.
  • 12. Qiagen N.V.
  • 13. Siemens AG
  • 14. Sysmex Corporation
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. LIVER CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENZYMES & ISOENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROWTH FACTORS & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR MARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ONCOFETAL & GLYCOPROTEIN ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGICAL BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & CRO LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023